Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Galieni

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|December 1, 1994
Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphomaR Stasi, P L Zinzani, P Galieni, et al.
European Journal of Haematology. Supplementum|January 1, 1989
Histology and immunohistology of bone marrow biopsy in multiple myelomaS Pileri, S Poggi, P Baglioni, et al.
Blood|May 23, 1998
Expression of the T-cell-specific tyrosine kinase Lck in normal B-1 cells and in chronic lymphocytic leukemia B cellsM B Majolini, M M D'Elios, P Galieni, et al.
Bone Marrow Transplantation|July 1, 1989
Normal myeloid progenitors (CFU-GM) in multiple myeloma: a preliminary study in view of autologous BMTR M Lemoli, G Visani, M Gobbi, et al.
European Journal of Haematology|January 1, 1997
2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disordersD Rondelli, F Lauria, P L Zinzani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1995
Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities?P Galieni, M Cavo, G Avvisati, et al.
European Journal of Haematology|January 1, 1995
Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphomaR Stasi, L Zinzani, P Galieni, et al.
Haematologica|November 1, 1988
Phase II study with a new alkylating agent (PTT-119) in lymphoid malignanciesS Tura, P Mazza, F Gherlinzoni, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomasS Tura, P Mazza, F Gherlinzoni, et al.
The American Journal of Pathology|March 1, 1993
Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomasL Leoncini, M T Del Vecchio, T Megha, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|December 1, 1994
Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphomaR Stasi, P L Zinzani, P Galieni, et al.
European Journal of Haematology. Supplementum|January 1, 1989
Histology and immunohistology of bone marrow biopsy in multiple myelomaS Pileri, S Poggi, P Baglioni, et al.
Blood|May 23, 1998
Expression of the T-cell-specific tyrosine kinase Lck in normal B-1 cells and in chronic lymphocytic leukemia B cellsM B Majolini, M M D'Elios, P Galieni, et al.
Bone Marrow Transplantation|July 1, 1989
Normal myeloid progenitors (CFU-GM) in multiple myeloma: a preliminary study in view of autologous BMTR M Lemoli, G Visani, M Gobbi, et al.
European Journal of Haematology|January 1, 1997
2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disordersD Rondelli, F Lauria, P L Zinzani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1995
Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities?P Galieni, M Cavo, G Avvisati, et al.
European Journal of Haematology|January 1, 1995
Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphomaR Stasi, L Zinzani, P Galieni, et al.
Haematologica|November 1, 1988
Phase II study with a new alkylating agent (PTT-119) in lymphoid malignanciesS Tura, P Mazza, F Gherlinzoni, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomasS Tura, P Mazza, F Gherlinzoni, et al.
The American Journal of Pathology|March 1, 1993
Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomasL Leoncini, M T Del Vecchio, T Megha, et al.
Pageof 6